Showing 37 Results
Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry
New study examines the role of NIH and industry in bringing new treatments into clinical settings.
NPC Comments on Proposed Changes for ICER Value Assessment Framework
NPC's comments highlight key concerns related to proposed changes to ICER's 2023 Value Assessment Framework.
NPC Comments on CMS' Drug Price Negotiation Counteroffer Information Collection Request
As CMS develops the detailed steps involved in the agency's drug pricing processes, NPC's comments highlight key shortcomings in the agency's counteroffer information collection request (ICR).
NPC Comments on CMS Information Collection Request for Negotiation Data Elements
NPC's comments offer input on the agency's latest efforts to implement the drug price-setting provisions of the Inflation Reduction Act through the design of a data collection process.
NPC Comments on CMS Medicare Drug Price Negotiation Program
NPC's comments highlight concerns about the agency's guidance regarding the implementation of Medicare Drug Price Negotiation and the potential for unintended consequences, including less…
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
Study shows the impact of a more holistic approach to assessing value and how it can help address gaps within conventional value assessment.
What Might Have Happened: The Impact of Interrupting Entry of Innovative Drugs on Disease Outcomes in the United States
A new NPC study shows how major drug innovations significantly improved patient health outcomes for six diseases with substantial mortality or morbidity.
The Impact of COVID-19 on Real-World Health Data and Research
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
Multi-Criteria Decision Analysis: Can It Help Make Value Assessment More Patient Centered?
This white paper identifies good practices and key considerations for integrating the patient voice into patient-centered multi-criteria decision analysis.
Do Patient Preferences Align with Value Frameworks? A Discrete-Choice Experiment of Patients with Breast Cancer
The study assessed patient preferences for aspects of breast-cancer treatments to evaluate the usual assumptions in scoring rubrics for value frameworks.
Underestimating the Value of an Intervention – The Case for Including Productivity in Value Assessments and Formulary Design
Research shows that including non-health care costs like productivity in value assessment frameworks can change the value assessment of interventions, impact on coverage decisions and subsequent…
Barriers and Solutions to the Inclusion of Broader Benefits in Biopharmaceutical Value Assessments
This study evaluated how institutional barriers prevent the inclusion of broader individual and societal benefits associated with new health care innovations from being considered when assessing the…